XML 16 R4.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Operating expenses:        
Research and development $ 5,392,777   $ 6,912,410  
Research and development   $ 985,081   $ 1,376,140
General and administrative 4,620,353 1,034,120 6,256,910 1,657,595
Transaction costs 0 0 5,765,407 0
Change in fair value of contingent consideration 0 0 (820,000) 0
Total operating expenses 10,013,130 2,019,201 18,114,727 3,033,735
Loss from operations (10,013,130) (2,019,201) (18,114,727) (3,033,735)
Other expenses:        
Loss on sale of NTN assets (50,000) 0 (9,648,173) 0
Other expense, net (22,187) (14,245) (24,751) (18,923)
Total other expenses (72,187) (14,245) (9,672,924) (18,923)
Net loss (10,085,317) (2,033,446) (27,787,651) (3,052,658)
Series A preferred stock dividend (7,806) 0 (7,806) 0
Net loss attributable to common stockholders $ (10,093,123) $ (2,033,446) $ (27,795,457) $ (3,052,658)
Net loss per common share - basic (in dollars per share) $ (0.24) $ (0.12) $ (0.79) $ (0.17)
Net loss per common share - diluted (in dollars per share) $ (0.24) $ (0.12) $ (0.79) $ (0.17)
Weighted average number of shares outstanding - basic (in shares) 42,448,188 17,583,489 35,187,292 17,542,750
Weighted average number of shares outstanding - diluted (in shares) 42,448,188 17,583,489 35,187,292 17,542,750